Go Deep
ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,650 | -8.6 | 3.08 | 0.02 | 1,077.09 |
| Oct 2026 | 18,516 | -8.8 | 3.15 | 0.02 | 1,100.44 |
| Oct 2026 | 17,953 | -9.5 | 3.47 | 0.02 | 1,212.65 |
| Oct 2026 | 18,153 | -9.4 | 3.36 | 0.02 | 1,169.73 |
| Oct 2026 | 17,977 | -9.6 | 3.46 | 0.02 | 1,206.06 |
| Oct 2026 | 17,471 | -10.4 | 3.75 | 0.02 | 1,306.57 |
| Oct 2026 | 17,437 | -10.5 | 3.77 | 0.02 | 1,309.96 |
| Oct 2026 | 17,542 | -10.3 | 3.71 | 0.02 | 1,286.55 |
ORIC Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -41,492,000.0 | -35,767,000.0 | -30,505,000.0 | -32,587,000.0 |
| EPS | -0.4 | -0.3 | -0.3 | -0.3 |
ORIC Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -129,468,000.0 | -127,847,000.0 | -100,697,000.0 | -89,122,000.0 | — |
| EPS | -1.5 | -1.8 | -2.0 | -2.2 | — |
ORIC Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 408,890,000.0 | 274,142,000.0 | 252,007,000.0 | 247,178,000.0 | — |
| Total Liabilities | 24,528,000.0 | 31,020,000.0 | 27,919,000.0 | 24,827,000.0 | — |
| Total Equity | 384,362,000.0 | 243,122,000.0 | 224,088,000.0 | 222,351,000.0 | — |
Owes vs Owns
ORIC Pharmaceuticals, Inc. owed $0.06 for every $1 it owned in Jun 2026, down from $0.10 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.06× | 0.06× | 0.11× | 0.11× | 0.10× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ORIC Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 68.8%Fixed assets (tangible) 0.6%Long-term investments 27.1%Other assets 3.5%
How it's funded — Dec 2025
Short-term debt 0.8%Payables 0.9%Other liabilities 4.2%Shareholders' equity 94.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 281.5 | 256.0 | 208.2 | 206.3 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 2.4 | 2.9 | 2.9 | 3.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 110.8 | 0.0 | 26.9 | 22.0 |
| Other assets | 14.2 | 15.3 | 14.1 | 15.7 |
| Liabilities & equity | ||||
| Short-term debt | 3.3 | 3.2 | 2.8 | 2.7 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 3.8 | 1.5 | 0.9 | 1.3 |
| Other liabilities | 17.4 | 26.3 | 24.2 | 20.8 |
| Shareholders' equity | 384.4 | 243.1 | 224.1 | 222.4 |
| Net tangible assets | 384.4 | 243.1 | 224.1 | 222.4 |
ORIC Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -110,970,000.0 | -112,662,000.0 | -85,688,000.0 | -75,143,000.0 | — |
| Investing Activities | -148,031,000.0 | 22,137,000.0 | -43,403,000.0 | -109,248,000.0 | — |
| Financing Activities | 245,264,000.0 | 126,547,000.0 | 85,658,000.0 | 25,225,000.0 | — |